Survodutide: the dual-hormone drug weaponizing glucagon’s forgotten talent — burning liver fat — while GLP-1 handles the appetite.

The GLP-1 agonist revolution transformed obesity treatment with a single receptor target. Semaglutide proved that 15% weight loss was achievable with a weekly injection. Tirzepatide proved that two receptors (GLP-1 plus GIP) could push that number above 20%. Retatrutide went further — three receptors, 24% weight loss in Phase II. Each generation has added complexity. Survodutide takes a different approach: fewer receptors than retatrutide, but a more targeted combination.

Survodutide (BI 456906), developed by Boehringer Ingelheim, is a dual GLP-1/glucagon receptor agonist. Where tirzepatide adds GIP to GLP-1, survodutide adds glucagon — a hormone that most people associate with raising blood sugar, not lowering body weight. But glucagon’s role in metabolism is broader than its acute glycemic effect: it drives thermogenesis, accelerates hepatic fat oxidation, and enhances lipolysis. These are precisely the mechanisms that make fatty liver disease — now called MASH (metabolic dysfunction-associated steatohepatitis) — survodutide’s most differentiated clinical application.

The Phase II results are published in two of medicine’s most respected journals. Blüher et al. reported the obesity data in Lancet Diabetes & Endocrinology (2024): 14.9% mean weight loss at 4.8 mg over 46 weeks by intention-to-treat analysis, or 18.7% among completers (PMID: 38330987). Sanyal et al. reported the MASH data in the New England Journal of Medicine (2024): up to 62% of participants showed MASH improvement without worsening fibrosis, and liver fat dropped by at least 30% in up to 67% of participants (PMID: 38847460). Four Phase III programs are now active: SYNCHRONIZE-1 and -2 for obesity, a cardiovascular outcomes trial (SYNCHRONIZE-CVOT), and LIVERAGE for MASH.

The dual mechanism positions survodutide between GLP-1 monotherapy and triple agonism — mechanistically more targeted than retatrutide, with a liver-specific angle that neither semaglutide nor tirzepatide was designed for. Whether that positioning translates to a distinct clinical niche depends on the Phase III results still to come.

Quick Facts: Survodutide at a Glance

What Is Survodutide?

Most drugs in the new obesity class target the GLP-1 receptor — the appetite-suppression pathway that semaglutide made famous. Tirzepatide added the GIP receptor. Retatrutide added all three: GLP-1, GIP, and glucagon. Survodutide takes a different route. It skips GIP entirely and pairs GLP-1 with the receptor that nobody expected to see in a weight loss drug: glucagon.

Survodutide (BI 456906) is a synthetic peptide engineered by Boehringer Ingelheim to act as a balanced co-agonist at both the GLP-1 receptor and the glucagon receptor (GCGR). The molecule includes a C18 fatty diacid modification that enables albumin binding in the bloodstream, extending the half-life to approximately three to five days — long enough to support once-weekly subcutaneous dosing. The compound was selected from a library of dual agonists based on its receptor-binding profile and pharmacokinetic properties (PMID: 38560764).

The glucagon component is what makes survodutide unusual. Glucagon has been understood primarily as the counter-regulatory hormone to insulin — it raises blood sugar. Using it in a weight loss drug seemed counterintuitive. But glucagon also drives thermogenesis through brown adipose tissue, accelerates fatty acid oxidation in the liver, and enhances lipolysis in white adipose tissue. When these catabolic effects are paired with GLP-1’s appetite suppression and glucose-dependent insulin secretion (which offsets glucagon’s blood sugar elevation), the result is a drug with a unique metabolic profile — particularly for patients with fatty liver disease, where the liver-directed fat-burning mechanism is directly therapeutic.

Origins and Development

The idea of using glucagon therapeutically for weight loss dates back further than most people realize. Glucagon was identified as a hyperglycemic hormone in the 1920s, but its role in energy expenditure was documented in the 1960s: glucagon infusions increased resting metabolic rate in humans, an effect traceable to thermogenesis and hepatic fat oxidation. The problem was obvious — you cannot give people a drug that raises blood sugar if the goal is metabolic health. The idea was shelved for decades.

The GLP-1 agonist class changed the equation. Semaglutide and liraglutide demonstrated that GLP-1R agonism could reliably suppress appetite and improve glycemic control. This created a pharmacological partner: what if GLP-1R agonism could offset glucagon’s hyperglycemic effect while preserving its catabolic benefits? Boehringer Ingelheim’s research team pursued this dual-agonist strategy through systematic peptide engineering, screening candidates for balanced GCGR/GLP-1R affinity and favorable pharmacokinetics (PMID: 38560764).

BI 456906 (later named survodutide) emerged from this program. Phase I studies established tolerability and the pharmacokinetic basis for weekly dosing. The Phase II obesity trial enrolled 387 adults starting in March 2021 (NCT04667377), with results published in Lancet Diabetes & Endocrinology in 2024. A separate Phase II trial tested dose-response effects on HbA1c and bodyweight in people with type 2 diabetes, with results published in Diabetologia in 2024 (PMID: 38095657). A third Phase II trial — the one that may define survodutide’s identity — tested the compound in MASH with fibrosis, published in the New England Journal of Medicine in July 2024 (PMID: 38847460).

Boehringer Ingelheim launched four Phase III programs: SYNCHRONIZE-1 (obesity without T2D; NCT06066515), SYNCHRONIZE-2 (obesity with T2D; NCT06066528), SYNCHRONIZE-CVOT (cardiovascular outcomes; NCT06077864), and LIVERAGE (MASH; NCT06632444). The company is pursuing simultaneous development in obesity and liver disease — a strategy that reflects the glucagon receptor’s unique position at the intersection of both conditions.

Mechanism of Action

GLP-1 Receptor Agonism

Survodutide’s GLP-1R activity provides the established incretin effects: glucose-dependent insulin secretion from pancreatic beta cells, glucagon suppression (partially offsetting the GCGR component’s hyperglycemic tendency), gastric emptying delay, and central appetite suppression via hypothalamic and brainstem GLP-1R. These are the same mechanisms exploited by semaglutide and liraglutide — well-characterized over two decades of GLP-1 pharmacology. In practical terms: GLP-1R activation makes you less hungry, keeps food in your stomach longer so you feel full sooner, and helps your pancreas respond to blood sugar more effectively.

Glucagon Receptor Agonism

GCGR agonism is where survodutide diverges from every approved GLP-1 drug and from tirzepatide. Glucagon receptor activation produces several catabolic effects:

Thermogenesis: Glucagon activates uncoupling protein 1 (UCP1) in brown adipose tissue, increasing resting energy expenditure. In animal models, GCGR agonism increases metabolic rate independently of physical activity. In practical terms, the body burns more calories at rest — a mechanism not seen with GLP-1R agonism alone.

Hepatic fat oxidation: This is survodutide’s signature effect. GCGR activation in hepatocytes drives fatty acid beta-oxidation — the metabolic pathway that breaks down stored triglycerides in liver cells. This is not a secondary consequence of weight loss; it is a direct pharmacological effect on liver metabolism. For patients with MASH, where excess liver fat drives inflammation and fibrosis, this mechanism is directly therapeutic.

Enhanced lipolysis: GCGR agonism promotes triglyceride breakdown in white adipose tissue, releasing fatty acids for oxidation. Combined with GLP-1R-mediated appetite suppression (which creates a caloric deficit), this produces preferential fat mass reduction.

Glucose balance: Here is the critical pharmacological trick. Glucagon alone raises blood sugar by stimulating hepatic glucose output — gluconeogenesis and glycogenolysis. In survodutide, GLP-1R-mediated insulin secretion and glucagon suppression offset this effect. The Phase II obesity trial (PMID: 38330987) and the T2D trial (PMID: 38095657) both confirmed that survodutide does not cause clinically significant hyperglycemia — the GLP-1 side successfully counterbalances the glucagon side.

Key Research: Phase II Obesity

The Landmark Phase II Trial

Blüher M, et al. Lancet Diabetes Endocrinol. 2024;12(3):162-173. PMID: 38330987

Design: Randomized, double-blind, placebo-controlled, dose-finding trial. N=387 adults with BMI ≥27 and at least one obesity-related comorbidity, without type 2 diabetes. Doses: 0.6, 2.4, 3.6, and 4.8 mg survodutide weekly, with dose escalation over approximately 16 weeks. Duration: 46 weeks.

Results at 46 weeks (treatment-policy estimand / intention-to-treat):

• 0.6 mg: −6.2%
• 2.4 mg: −12.5%
• 3.6 mg: −13.2%
• 4.8 mg: −14.9%
• Placebo: −2.8%

Trial-product estimand (completers, who represented 60.4% of those randomized): up to −18.7% at 4.8 mg.

These are the two numbers that both matter and that readers must understand the difference between. The 14.9% figure reflects what happened to everyone randomized to that dose, including people who dropped out (some of whom regained weight). The 18.7% figure reflects what happened to people who completed the full 46-week course. Both are valid — they answer different questions.

82.8% of participants at 4.8 mg achieved ≥5% weight loss (vs 25.9% placebo). Up to 40% of those on the two highest doses achieved ≥20% weight loss — a threshold historically associated with bariatric surgery outcomes.

Blood Pressure Post Hoc

A post hoc analysis of the same Phase II obesity trial found that survodutide significantly improved systolic and diastolic blood pressure — an expected secondary benefit of weight loss combined with the metabolic effects of dual agonism (PMID: 39582349).

Key Research: Phase II in MASH

The NEJM MASH Trial

Sanyal AJ, et al. N Engl J Med. 2024;391(4):311-319. PMID: 38847460

Design: Randomized, double-blind, placebo-controlled, 48-week Phase II trial. Adults with biopsy-confirmed MASH and fibrosis stage F1 through F3. Doses: 2.4, 4.8, and 6.0 mg survodutide weekly. Two phases: 24-week rapid dose escalation, then 24-week maintenance.

Primary endpoint — improvement in MASH without worsening of fibrosis:

• 2.4 mg: 47%
• 4.8 mg: 62%
• 6.0 mg: 43%
• Placebo: 14%

Liver fat reduction ≥30%:

• 2.4 mg: 63%
• 4.8 mg: 67%
• 6.0 mg: 57%
• Placebo: 14%

The 4.8 mg dose outperformed the 6.0 mg dose on the primary endpoint — a result the investigators attributed to higher discontinuation rates and more GI adverse events at the highest dose. The dose-response was not linear, and it followed a quadratic model (P<0.001).

This trial was published alongside the tirzepatide MASH trial (SYNERGY-NASH, PMID: 38856224) in the same issue of the NEJM — a deliberate editorial decision that positioned both compounds as leading candidates for MASH pharmacotherapy.

Cirrhosis Pharmacokinetics

A separate study characterized survodutide’s pharmacokinetics and safety in patients with compensated or decompensated cirrhosis (PMID: 38857788). Key findings: no dose adjustment needed based on liver function, survodutide was generally tolerable, and exploratory endpoints showed improvements in liver fat content, fibrosis markers, and body weight. This is significant because MASH frequently progresses to cirrhosis, and knowing the drug is safe in cirrhotic patients expands its potential treatment population.

Key Research: Type 2 Diabetes

Phase II in T2D

Heise T, et al. Diabetologia. 2024. PMID: 38095657

Design: Randomized, double-blind, placebo-controlled trial with an open-label semaglutide comparator. Adults with type 2 diabetes. Doses: 0.3, 0.9, 1.8, and 2.7 mg survodutide once weekly (or 1.2 and 1.8 mg twice weekly). Duration: 16 weeks.

Results: Dose-dependent reductions in HbA1c and bodyweight across all survodutide groups. The inclusion of an open-label semaglutide arm allowed preliminary comparison, though the trial was not powered for formal head-to-head analysis. This trial established that survodutide’s glycemic effects are clinically meaningful — the GCGR component does not negate GLP-1R-mediated glucose control.

Phase III Programs

Boehringer Ingelheim is pursuing survodutide across four Phase III programs simultaneously — an aggressive strategy reflecting the compound’s dual-indication potential.

Trial Name	Population	Primary Endpoint	Status (April 2026)
SYNCHRONIZE-1 (NCT06066515)	Adults with obesity, without T2D	Percent change in body weight	Actively recruiting (PMID: 41187967)
SYNCHRONIZE-2 (NCT06066528)	Adults with obesity and T2D	Percent change in body weight + HbA1c	Actively recruiting (PMID: 41216778)
SYNCHRONIZE-CVOT (NCT06077864)	Adults with obesity + CV disease or CKD	Cardiovascular outcomes	Rationale and design published (PMID: 39453356)
LIVERAGE (NCT06632444)	Adults with MASH	Liver histology / MASH resolution	Active

This breadth of trials is significant. Boehringer Ingelheim is betting that survodutide will work not just for weight loss, but for fatty liver disease — an indication where the glucagon mechanism provides a stronger theoretical rationale than any competitor. If the MASH trials succeed, survodutide could become the first drug approved specifically for liver fat reduction through a direct hepatic mechanism. If they fail, it competes head-to-head with tirzepatide and retatrutide on weight loss alone — a fight it may not win on magnitude.

Claims vs. Evidence

Below is a table of frequently made claims about survodutide and how the current evidence evaluates them:

Claim	Evidence / Verdict	Status Badge
"Survodutide produces ~19% weight loss"	Phase II (N=387, 46 wk): −14.9% by ITT at 4.8 mg; −18.7% by completers analysis. The 19% figure reflects completers only — the ITT result is 14.9%. Both are valid but answer different questions. PMID: 38330987	Partially Supported
"The glucagon component adds benefit over GLP-1 alone"	GCGR agonism adds thermogenesis and hepatic fat oxidation to GLP-1’s appetite suppression. Weight loss exceeds GLP-1 monotherapy historical benchmarks (cross-trial comparison only; no head-to-head vs. semaglutide).	Mechanistically Supported
"Survodutide treats fatty liver disease (MASH)"	Phase II NEJM: 62% MASH improvement at 4.8 mg vs 14% placebo; liver fat ≥30% reduction in 67%. Phase III (LIVERAGE) is running. PMID: 38847460	Phase II Supported
"Survodutide is better for liver disease than semaglutide or tirzepatide"	No head-to-head trial exists. Cross-trial comparisons suggest competitive MASH response rates, but different trial designs, patient populations, and endpoints make direct comparison unreliable. All three compounds have MASH programs.	Unproven
"Survodutide produces less nausea than triple agonists"	No comparative trial data. Phase II GI AE rate was 75%, consistent with the GLP-1 class. The claim that removing GIP reduces nausea is mechanistically plausible but unproven.	Unproven
"The dual mechanism is simpler and safer than triple agonism"	Fewer receptor targets does not automatically mean fewer side effects. No safety comparison exists. Phase II AE rates are class-consistent.	Unproven
"Survodutide reverses liver fibrosis"	Phase II: fibrosis improved ≥1 stage in 34–36% of survodutide groups vs 22% placebo. Statistically significant dose-response, but this was a secondary endpoint. "Reversal" overstates what was observed. PMID: 38847460	Partially Supported
"Survodutide works in people with cirrhosis"	A PK/tolerability study (PMID: 38857788) showed survodutide is tolerable in compensated and decompensated cirrhosis with exploratory improvements in liver markers. Not a controlled efficacy trial.	Preliminary
"Survodutide is available for purchase"	No. Phase III investigational compound available only through clinical trials. Not commercially available. No compounded or gray-market supply exists.	FALSE
"Survodutide’s half-life is 10–14 days"	Published data supports ~3–5 days based on PK profiling and weekly dosing rationale. The 10–14 day figure appearing on some sites is incorrect. PMID: 38560764	FALSE

We currently don’t have any vetted partners for this compound. Check back soon.

Side Effects and Safety

Phase II Adverse Event Profile

The Phase II obesity trial (PMID: 38330987) provides the most comprehensive safety data currently available:

• Any adverse event: 91% of survodutide recipients (281/309) vs 75% of placebo (58/77)
• Gastrointestinal adverse events: 75% of survodutide recipients (232/309) vs 42% of placebo (32/77)
• Most common GI events: Nausea, vomiting, diarrhea — consistent with the GLP-1 class
• Discontinuation due to adverse events: Higher in survodutide groups, dose-dependent
• Completion rate: 60.4% completed the 46-week treatment period — notable dropout, primarily due to GI tolerability during dose escalation

GCGR-Specific Considerations

Blood glucose variability: GCGR agonism increases hepatic glucose output. While GLP-1R co-agonism offsets this effect in published trials, patients with significant insulin resistance or advanced type 2 diabetes may experience transient glucose excursions during dose titration. The T2D trial (PMID: 38095657) did not report clinically significant hyperglycemia, but longer-term data from SYNCHRONIZE-2 will be informative.

Amino acid metabolism: Glucagon stimulates hepatic amino acid catabolism. Chronic GCGR agonism could theoretically affect lean body mass preservation during weight loss. Body composition data from Phase III will be critical.

Liver enzyme elevations: ALT/AST changes during GCGR agonism require monitoring, particularly in the MASH population where baseline liver enzymes may already be elevated.

What We Do Not Know

Phase II trials are designed to find doses and generate signals, not to establish long-term safety. Specific unknowns include: cardiovascular outcomes (SYNCHRONIZE-CVOT will address this), long-term safety beyond 48 weeks, effects on lean body mass composition, safety in patients with more advanced liver disease, and interaction with other metabolic medications.

Regulatory and Legal Status

FDA Status

Not approved. Phase II/III investigational drug. No NDA (New Drug Application) has been submitted. Boehringer Ingelheim has not publicly disclosed a target NDA submission date.

WADA Status

Survodutide is not explicitly named on the WADA Prohibited List. However, as a non-approved pharmacological substance, it falls under Section S0 — "Non-Approved Substances," which prohibits all pharmacological substances not addressed by subsequent sections if they are not currently approved for human therapeutic use by any governmental regulatory health authority. Athletes subject to WADA testing should consider survodutide prohibited.

Clinical Trial Access

Survodutide is available only through enrollment in active clinical trials (SYNCHRONIZE-1, -2, -CVOT; LIVERAGE). ClinicalTrials.gov lists enrollment sites.

Commercial Availability

None. Survodutide is not available through pharmacies, compounding pharmacies, or peptide vendors. Any product sold as "survodutide" outside a clinical trial is unverified and should be considered fraudulent.

Dosing: Published Research

All published dosing data for survodutide comes from controlled clinical trials conducted by Boehringer Ingelheim. The following tables summarize the protocols used across Phase II and Phase III.

Key observations: all doses were subcutaneous injections given once weekly (except the twice-weekly T2D arms). Escalation was gradual in the obesity trial. The MASH trial used a faster 24-week escalation that contributed to higher dropout at 6.0 mg. Phase III trials use dose flexibility — clinicians can adjust within the 3.6–6.0 mg range based on tolerability.

Dosing: Community Practices

Unlike semaglutide, tirzepatide, or even retatrutide, survodutide has no compounding pharmacy supply, no research peptide vendor ecosystem, and no community dosing culture. This is a pure clinical-trial compound at this stage. If and when survodutide is FDA-approved, community dosing practices will likely emerge — this section will be updated at that time.

Related Compounds

Survodutide occupies a specific position in the metabolic pharmacotherapy landscape: mechanistically between GLP-1 monotherapy and triple agonism, with a liver-directed component that creates differentiation for MASH.

Compound	Type	Primary Target	Half-Life	FDA Status	WADA Status	Evidence Tier	Weight Loss Efficacy	Route	Mechanism Class	Key Differentiator
Semaglutide	Synthetic GLP-1 receptor agonist peptide	GLP-1R	~7 days	FDA-approved (Wegovy, Ozempic)	Prohibited — S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics)	Tier 1 — Approved Drug	Up to 22% body weight reduction (Phase III)	Subcutaneous injection (weekly)	GLP-1 agonist	Longest half-life in class; once-weekly dosing. Identical sequence to human GLP-1 except for fatty acid moiety for albumin binding
Tirzepatide	Synthetic dual GLP-1R/GIPR agonist peptide	GLP-1R / GIPR	~5 days	FDA-approved (Zepbound, Mounjaro)	Prohibited — S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics)	Tier 1 — Approved Drug	Up to 22% body weight reduction (Phase III SURMOUNT-3)	Subcutaneous injection (weekly)	Dual GLP-1/GIP agonist	Dual agonism produces greater weight loss than GLP-1 monotherapy. Glucose-dependent mechanism
Retatrutide	Synthetic triple GLP-1R/GIPR/GcgR agonist peptide	GLP-1R / GIPR / GcgR	~5 days	Phase III clinical trials (not yet approved)	Prohibited — S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) — projected	Tier 2 — Clinical Trials (Phase III)	Up to 24% body weight reduction (Phase II)	Subcutaneous injection (weekly)	Triple GLP-1/GIP/glucagon agonist	Broadest receptor coverage in development. Glucagon pathway adds hepatic glucose production suppression
Liraglutide	Synthetic GLP-1 receptor agonist peptide	GLP-1R	~13 hours	FDA-approved (Saxenda, Victoza)	Prohibited — S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics)	Tier 1 — Approved Drug	Up to 8% body weight reduction (Phase III SCALE)	Subcutaneous injection (daily)	GLP-1 agonist	First GLP-1 RA approved for weight management. Daily dosing. Well-established long-term safety data
Orforglipron	Non-peptide small-molecule GLP-1 receptor agonist	GLP-1R	~11 hours	FDA-approved (Foundayo)	Prohibited — S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics)	Tier 1 — Approved Drug	Up to 15% body weight reduction (Phase II interim)	Oral (small molecule)	GLP-1 agonist (oral)	First oral non-peptide GLP-1 RA approved for weight management. Room-temperature stable, no injection required
CagriSema	Synthetic fixed-ratio combination (semaglutide + cagrilintide)	GLP-1R / AmylinR	~7 days (semaglutide) / ~7 days (cagrilintide)	Phase III clinical trials (pending)	Prohibited — S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) — projected	Tier 2 — Clinical Trials (Phase III)	Up to 20% body weight reduction (Phase II interim)	Subcutaneous injection (weekly)	GLP-1/amylin dual agonist	Combines GLP-1 RA with long-acting amylin analog. Amylin pathway targets satiety and gastric emptying synergistically
Survodutide	Synthetic dual GLP-1R/GcgR agonist peptide	GLP-1R / GcgR	~3–4 days	Phase II clinical trials (pending)	Prohibited — S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) — projected	Tier 2 — Clinical Trials (Phase II)	Up to 18% body weight reduction (Phase II interim)	Subcutaneous injection (weekly)	GLP-1/glucagon dual agonist	Glucagon pathway without GIP agonism. May offer weight loss with reduced nausea vs. triple agonists
AOD-9604	Modified fragment of GH (amino acids 177–191)	GH mimetic (fragment-based)	~2–4 hours	Not FDA-approved	Prohibited — S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) — as GH fragment	Tier 3 — Pilot / Limited Human Data	~2–3% body weight reduction (limited human data)	Subcutaneous injection	GH C-terminus analog (lipolytic)	Smaller peptide (15 amino acids) derived from GH. Lipolytic effect without GH-typical muscle anabolism claims
5-Amino-1MQ	Synthetic small molecule quinone metabolite analog	NNMT inhibitor	~6–8 hours	Not FDA-approved	Not WADA-listed — emerging research compound	Tier 4 — Preclinical Only	~5–8% body weight reduction (mouse models only; limited human data)	Oral (small molecule)	NNMT inhibition (NAD+ pathway)	Non-peptide. Targets mitochondrial NAD+ metabolism. No human safety/efficacy data published
MOTS-c	Synthetic mitochondrial open-reading-frame peptide (13 amino acids)	AMPK activator (AMP-kinase pathway)	~2–4 hours	Not FDA-approved	Prohibited — S0 (Non-Approved Substances)	Tier 4 — Preclinical Only	Modest weight reduction (animal models); no published human trials	Subcutaneous injection	Mitochondrial-derived peptide analog	Endogenous mitochondrial peptide. Activates AMPK/SIRT pathway. Only mouse models published
Tesamorelin	Synthetic GHRH analog (1-44 amino acids, GHRH-analogue with acyl modification)	GHRH-R	~26 minutes	FDA-approved (Egrifta for lipodystrophy in HIV)	Prohibited — S2 (GHRH analog)	Tier 1 — Approved Drug	~2–4% visceral fat reduction (HIV lipodystrophy indication)	Subcutaneous injection (daily)	GHRH analog	Only GH secretagogue approved by FDA for visceral adiposity. Raises GH indirectly via pituitary. Limited weight loss data in non-HIV populations

vs. Semaglutide (Ozempic/Wegovy)

Semaglutide targets GLP-1R only. Approved for obesity, T2D, and cardiovascular risk reduction. ~15% weight loss in Phase III. Survodutide adds GCGR agonism and shows comparable weight loss in Phase II (14.9% ITT), but no direct comparison exists. Semaglutide has years of real-world safety data that survodutide lacks.

vs. Tirzepatide (Mounjaro/Zepbound)

Tirzepatide targets GLP-1R + GIPR. Approved for obesity, T2D, and OSA. ~22% weight loss in Phase III. Survodutide targets GLP-1R + GCGR — a different receptor pair. Tirzepatide has superior weight loss data and three FDA approvals. Survodutide’s differentiator is the liver-directed GCGR mechanism for MASH.

vs. Retatrutide

Retatrutide targets all three: GLP-1R + GIPR + GCGR. Phase II: ~24% weight loss. Still in Phase III (Eli Lilly). Retatrutide includes survodutide’s GCGR mechanism plus GIP, so it covers the broadest receptor profile. Whether three targets outperform two depends on Phase III results from both compounds.

vs. CagriSema

CagriSema is a co-formulation of cagrilintide (amylin analog) and semaglutide (GLP-1R agonist). It targets the amylin receptor and GLP-1R — a completely different receptor pair than survodutide. Phase III: ~22.7% weight loss. Different mechanism, different liver profile.

Frequently Asked Questions

Summary and Key Takeaways

Survodutide (BI 456906) is Boehringer Ingelheim’s dual GLP-1/glucagon receptor agonist — a once-weekly injection that combines appetite suppression with glucagon-driven fat burning, particularly in the liver. Three Phase II RCTs are published in top-tier journals. Four Phase III programs are active. It is not approved, not available, and not yet proven at scale.

Key Takeaways

1. Phase II weight loss: 14.9% (ITT) to 18.7% (completers) at the highest dose over 46 weeks — above GLP-1 monotherapy, below tirzepatide and retatrutide (cross-trial comparison).
2. MASH data is the differentiator. The NEJM Phase II trial showed 62% MASH improvement at 4.8 mg vs 14% placebo, with liver fat reduction in up to 67%. This is the strongest evidence for survodutide’s unique clinical niche.
3. Glucagon does the liver work. The GCGR component drives hepatic fat oxidation directly — not just as a secondary consequence of weight loss. This mechanism is unique among the approved and late-stage obesity drugs.
4. Phase III is the next chapter. Four active programs (SYNCHRONIZE-1, -2, -CVOT; LIVERAGE) will determine whether Phase II results hold at scale and whether survodutide earns FDA approval.
5. Not available outside trials. No commercial, compounded, or gray-market supply exists. Any product claiming to be survodutide outside a clinical trial is unverified.
6. Safety is class-consistent but dropout is notable. 75% GI adverse events, 60% trial completion. Tolerable for most but not all.
7. Positioned between mono and triple agonism. Fewer targets than retatrutide, different targets than tirzepatide, stronger liver rationale than semaglutide. Whether this positioning becomes a clinical advantage depends on Phase III.

Verdict Recapitulation

Survodutide earns the "Reasonable Bet" label because Phase II data is published in two of medicine’s most respected journals, the dual-agonist mechanism is pharmacologically coherent, and the MASH data provides genuine differentiation. But it is not proven at Phase III scale. FDA approval is not guaranteed. Long-term safety beyond 48 weeks is unknown. If you’re considering it, read the data, talk to a provider, and understand that survodutide is not available outside clinical trials — this is not a drug you can buy yet.

Where to Source Survodutide

Survodutide is not commercially available. It is an investigational drug accessible only through clinical trial enrollment. Boehringer Ingelheim lists active enrollment sites on ClinicalTrials.gov:

• SYNCHRONIZE-1 — Obesity without T2D (NCT06066515)
• SYNCHRONIZE-2 — Obesity with T2D (NCT06066528)
• SYNCHRONIZE-CVOT — Cardiovascular outcomes (NCT06077864)
• LIVERAGE — MASH (NCT06632444)

Further Reading and Resources

If you want to go deeper on survodutide, the evidence landscape for weight-loss peptides, or the methodology behind how we evaluate this research, these are the places worth your time.

On Peptidings

• Retatrutide: What the Research Actually Shows — The triple agonist that includes survodutide’s GCGR mechanism plus GIP.
• Tirzepatide: What the Research Actually Shows — The current market leader; dual GLP-1/GIP agonist.
• Semaglutide: What the Research Actually Shows — The GLP-1 benchmark that survodutide aims to surpass.
• Liraglutide: What the Research Actually Shows — The first-generation GLP-1 agonist.
• Weight Loss & Metabolic Cluster Hub — All cluster A compounds compared.
• Evidence Levels Guide — How Peptidings classifies evidence tiers.
• How to Read a Study — Understanding trial design and estimands.
• Half-Lives and Dosing Guide — Why half-life determines dosing frequency.

External Resources

• PubMed — Biomedical Research Database — Search for "Survodutide" or related terms to access published studies.
• ClinicalTrials.gov — Check for any registered or ongoing survodutide trials that may be recruiting.

Selected References and Key Studies

1. Blüher M, et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 2024;12(3):162-173. PubMed
2. Sanyal AJ, et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med. 2024;391(4):311-319. PubMed
3. Heise T, et al. Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes. Diabetologia. 2024. PubMed
4. Ambery P, et al. Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis. J Hepatol. 2024. PubMed
5. Knerr PJ, et al. The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection. Eur J Pharmacol. 2024. PubMed
6. Klonoff DC, et al. Survodutide, a glucagon receptor/glucagon-like peptide-1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis. 2024. PubMed
7. Frias JP. Perspectives in weight control in diabetes — Survodutide. Diabetes Obes Metab. 2023. PubMed
8. Roux CW, et al. Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE-1). 2025/2026. PubMed
9. Baseline characteristics in the SYNCHRONIZE-2 randomized phase 3 trial of survodutide. 2025/2026. PubMed
10. Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE-1 and -2). 2024. PubMed
11. Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial. JACC Heart Fail. 2024. PubMed
12. Survodutide in MASH: bridging the gap between hepatic and systemic metabolic dysfunction. 2024. PubMed